

Category

Best Biotechnology Product

General Information**Company Name ***

Bavarian Nordic

Product/Solution Name *

VINKUNYA (Chikungunya Vaccine, Recombinant)

Compound/Tech Name*

Recombinant Chikungunya Virus-Like Particle Vaccine

Trade Name *

VIMKUNYA

Corporate Name *

Bavarian Nordic

Date of Approval *

2025-02-14

Indications *

VIMKUNYA is a vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older. (Approved under accelerated approval based on neutralizing antibody levels; continued approval may be contingent on confirmatory trials.)

words remaining :

461

Therapeutic Areas *

Viral vaccine / infectious disease prevention (tropical and expanding geographic risk areas)

words remaining :

488

*Kindly clearly label your files with company name and asset name.

Attached Files:

- [Bavarian Nordic Corporate Portfolio Video.mp4](#)

Background information and need for drug / device

(please be as specific as possible in your description; limit 500 words)

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes fever, rash, and often debilitating polyarthralgia. While symptoms typically resolve in 1-2 weeks, 2 in 5 patients may

experience long-term symptoms such as persistent joint pain or musculoskeletal discomfort that can last for months or even years. In severe cases, ~1 in 5 patients may require hospitalization.

Climate change and increased global travel have expanded the geographic range of CHIKV, leading to outbreaks in regions previously unaffected, including parts of southern Europe and the Americas. Despite this, preventive tools have been limited. Until recently, no vaccine was available in the U.S. to help protect adolescents or travelers at increased risk of exposure.

words remaining :

389

*Kindly clearly label your files with company name and asset name.

History of the development of the solution/product *
(please be as specific as possible in your description; 500 words)

Scientific origin: The VLP platform behind VIMKUNYA® was originally developed by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. NIH, and later licensed to Bavarian Nordic.

Vaccine design: VIMKUNYA is a recombinant, adjuvanted virus-like particle (VLP) vaccine that mimics the chikungunya virus structurally but contains no genetic material-meaning it cannot infect cells or replicate.

Mechanism of action: The vaccine's antigenic components (E1, E2, and capsid proteins) self-assemble into VLPs, inducing virus-neutralizing antibodies without the use of live virus.

Urgency & public health need: Chikungunya virus (CHIKV) causes symptoms ranging from fever and rash to severe, often long-lasting joint pain. There is currently no specific treatment for chikungunya.

- Chikungunya outbreaks have occurred in over 110 countries.
- In naïve populations, outbreaks can affect 50-70% of the population. (Flandes X, et al. Vaccine. 2023; <https://doi.org/10.1016/j.vaccine.2023.07.069>)
- During 2024, approximately 620,000 chikungunya cases were reported worldwide.
- Up to 2 in 5 patients may suffer long-term complications such as chronic arthralgia and musculoskeletal pain.
- Geographic spread is expanding due to climate change and global travel, with outbreaks now occurring in regions like southern Europe and the Americas.

Preclinical and clinical development: Bavarian Nordic conducted comprehensive preclinical safety evaluations, including toxicology and immunogenicity:

- Three Phase 2 trials
- Two pivotal Phase 3 trials in adolescents/adults (12-64 years) and older adults (≥65 years)
- Over 4,000 participants were enrolled across all five studies.

Phase 3 Immunogenicity outcomes:

- In individuals aged 12-64, 97.8% achieved seroresponse at Day 22
- 47% of people ages 12-64 started to develop the expected immune response against chikungunya in as little as 1 week. Almost everyone developed a response by Day 15 (97% for people 12-64 and 82% for people 65+).
- In adults aged ≥65, 87.3% achieved seroresponse at Day 22
- Persistence of antibodies observed through Day 183

Study design: Both Phase 3 trials were randomized, double-blind, and placebo-controlled, with serum neutralizing antibody levels at Day 22 as a primary endpoint.

Safety profile:

- In the 12-64 age group, common reactions: injection site pain (23.7%), fatigue (19.9%), headache (18.0%), and myalgia (17.6%)
- In adults ≥65: most common were myalgia and fatigue (both 6.3%)
- Adverse reactions were primarily mild to moderate and transient, with no significant safety signals reported.

Regulatory milestone: In February 2025, the U.S. FDA granted accelerated approval based on VIMKUNYA's safety profile and neutralizing antibody levels.

Ease of use: VIMKUNYA is administered as a single intramuscular dose in a pre-filled syringe, requiring no reconstitution- it is an innovative technology for an underreported disease that can cause a significant burden on public health systems.

Conclusion: VIMKUNYA is the first and only VLP vaccine for chikungunya approved in the U.S. for individuals 12 and older, representing over a decade of translational research and clinical progress. It delivers on an urgent public health need with a novel and highly targeted tool to help prevent chikungunya.

words remaining :

15

*Kindly clearly label your files with company name and asset name.

Why this drug or device is innovative, the broad implications for future research, and/or how it will improve the human condition *

VIMKUNYA represents a first-in-class advancement in chikungunya prevention:

- Virus-Like Particle (VLP) Platform: Mimics the external structure of live virus but does not contain genetic material and cannot infect cells or replicate.
- First and Only VLP Vaccine for Chikungunya in the U.S.: Designed to help protect individuals aged 12 years and older who travel to or reside in regions where CHIKV is endemic or emerging.
- Single-Dose, Pre-Filled Syringe: Administered as a single 0.8 mL intramuscular injection with no reconstitution required.

words remaining :

418

*Kindly clearly label your files with company name and asset name.

Attached Files:

- [USCHIK2400023_Clean.mp4](#)

Please provide appropriate references (PubMed, Abstract, Website) *

1. Advisory Committee on Immunization Practices. Recommendations for use of chikungunya vaccine among travelers. Available at: <https://www.cdc.gov/acip/vaccine-recommendations/index.html>. Accessed April 28, 2025
2. Amaral JK, et al. Viruses. 2019; 11:289

3. ANRS. Chikungunya emergence unit. Available at: <https://anrs.fr/en/emergence-units/chikungunya-emergence-unit/>. Accessed March 26, 2025
4. Ayu SM, et al. *Am J Trop Med Hyg*. 2010; 83:1245-1248
5. Bartholomeeusen K, et al. *Nat Rev Dis Primers*. 2023; 9:17
6. Bertolotti A, et al. *PLoS Negl Trop Dis*. 2020; 14:e0007327
7. Bettis AA, et al. *PLoS Negl Trop Dis*. 2022; 16:e0010069
8. Boggild AK, et al. *JAMMI*. 2016; 1:8-16
9. Burt FJ, et al. *Lancet Infect Dis*. 2017; 17:e107-e117
10. Caputo B, et al. *PLoS Negl Trop Dis*. 2020; 14:e0008159
11. Centers for Disease Control and Prevention. Areas at Risk for Chikungunya. Available at: https://www.cdc.gov/chikungunya/data-maps/?CDC_AAref_Val=https://www.cdc.gov/chikungunya/geo/. Accessed March 25, 2025.
12. Centers for Disease Control and Prevention. Chikungunya virus in the US. Available at: https://www.cdc.gov/chikungunya/data-maps/chikungunya-us.html?CDC_AAref_Val=https://www.cdc.gov/chikungunya/geo/chikungunya-in-the-us.html. Accessed March 25, 2025
13. Centers for Disease Control and Prevention. Chikungunya Yellow Book 2026. Available at: <https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/chikungunya.html>. Accessed April 23, 2025
14. Centers for Disease Control and Prevention. Clinical testing and diagnosis for chikungunya viral disease. Available at: <https://www.cdc.gov/chikungunya/hcp/diagnosis-testing/index.html#:~:text=Chikungunya%20virus%20antibodies%20normally%20develop,acute%2Dpha>. Accessed May 1, 2025
15. Centers for Disease Control and Prevention. Increased Chikungunya Virus Activity in Paraguay and Associated Risk to Travelers. Available at: <https://emergency.cdc.gov/han/2023/han00487.asp>. Accessed April 28, 2025
16. Chen R, et al. *mBio*. 2021; 12:e02738-21
17. Chikungunya in Réunion: week of March 31 to April 6, 2025, 2025. Available at: <https://www.lareunion.ars.sante.fr/chikungunya-la-reunion-semaine-du-24-au-30-mars-2025>. Accessed April 17, 2025
18. ClinicalTrials Arena. FDA approval of Valneva's IXCHIQ brings world's first chikungunya vaccine to market. Available here. Accessed January 2024
19. Couderc T & Lecuit M. *Antivir Res*. 2015; 121:120-131
20. de Andrade MMO, et al. *Trop Med Int Health*. 2022; 27:925-933
21. de Lima Cavalcanti TYV, et al. *Viruses* 2022; 14:969
22. de Souza WM, et al. *Lancet Reg Health Am*. 2024; 30:100673
23. Doran C, et al. *BMC Health Serv Res*. 2023; 23:1247
24. Doran C, et al. *BMC Infect Dis*. 2022; 16: e0010142
25. Doran C, et al. *PLoS Neg Trop Dis*. 2022; 16:e0010142
26. Doran Y, et al. *PLoS Negl Trop Dis*. 2022; 17: e0011359
27. Elsinga J, et al. *PloS Negl Trop Dis*. 2017; 11: e0005987
28. Estallo EL, et al. *Lancet Reg Health AM*. 2023; 23:100542
29. European Centre for Disease Prevention and Control. Communicable disease threats report, week 50, 7–13 December 2024. Available at: <https://www.ecdc.europa.eu/sites/default/files/documents/Communicable-disease-threats-report-week-50-2024.pdf>. Accessed April 22, 2025
30. European Centre for Disease Prevention and Control. Factsheet about chikungunya. Available at: <https://www.ecdc.europa.eu/en/chikungunya/facts/factsheet>. Accessed April 28, 2025

31. Feldstein LR, et al. PLoS Negl Trop Dis. 2019; 13:e0007563
32. Ferreira AS, et al. Rev Inst Med Trop Sao Paulo. 2022; 63:e16
33. Ferreira de Almeida I, et al. Lancet Reg Health Am. 2023; 25:100571
34. Furuya-Kanamori L, et al. BMC Infect Dis. 2016; 16:84
35. High Authority of Health. Use of the IXCHIQ vaccine in the context of the chikungunya epidemic in the territories of Réunion and Mayotte. Available at: https://www.has-sante.fr/upload/docs/application/pdf/2025-03/avis_-_utilisation_du_vaccin_ixchic_dans_le_contexte_epidémique_de_chikungunya_dans_les_territoires_de_l
Accessed March 26, 2025
36. Hossain MS, et al. PLoS Negl Trop Dis. 2018; 12:e0006561
37. Josseran L, et al. Emerg Infect Dis. 2006; 12:1994-1995
38. Kantele A. Euro Surveill. 2019; 24:1-4
39. Kay J et al. Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi5-9
40. Kraemer MUG, et al. Nat Microbiol. 2019; 4:901
41. Lindsey NP, et al. Am J Trop Med Hyg. 2018; 98:192-197
42. Liunbruno GM, et al. Blood Transfus. 2008; 6:199-210
43. Mora-Salamanca AF, et al. J Infect Dis. 2020; 97:81-89
44. Murugan SB & Sathishkumar R. Asian Pacific Journal of Tropical Medicine. 2016; 9:933–937
45. Ouest France. Chikungunya: first imported case in Mayotte from Réunion, vaccination recommended for seniors. Available at: <https://www.ouest-france.fr/sante/vaccin/chikungunya-a-la-reunion-la-vaccination-des-plus-de-65-ans-et-de-certains-adultes-recommandee-eadbc8e4-f9a5-11ef-a6a4-567d76e1951c>. Accessed March 26, 2025
46. Paixão ES, et al. Trans R Soc Trop Med Hyg. 2018; 112:301-316
47. Pan American Health Organization Chikungunya weekly report. Available at: <https://www3.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-weekly-en.html>. Accessed April 22, 2025;
48. Sahadeo N, et al. PLoS Negl Trop Dis. 2015; 9:e0004199
49. Sante publique France. Chikungunya and dengue fever in Réunion. Bulletin of February 25, 2025. Available at: <https://www.santepubliquefrance.fr/regions/ocean-indien/documents/bulletin-regional/2025/chikungunya-et-dengue-a-la-reunion.-bulletin-du-25-fevrier-2025>. Accessed March 2025
50. Schilte C, et al. PLoS Negl Trop Dis. 2013; 7:e2137
51. Schwartz KL, et al. CMAJ. 2014; 186:772-774
52. Schwartz O, et al. Nat Rev Microbiol. 2010; 8:491-500
53. Silva LA & Dermody TS. J Clin Invest. 2017; 127:737-749
54. Simon F, et al. Pathogens 2022; 11:989
55. Song BH, et al. J Neuroimmunol. 2017; 308:50-64
56. Tanabe ISB, et al. Front Cell Infect Microbiol. 2018; 8:1-15
57. Thiberville SD, et al. Antiviral Res. 2013; 99:345-70
58. Torales M, et al. MMWR Morb Mortal Wkly Rep. 2023; 72:636-638
59. van Aalst M, et al. Travel Med Infect Dis. 2017; 15:8-22
60. Wahid B, et al. Int J Infect Dis. 2017; 58:69-76
61. Weaver SC & Lecuit M. N Engl J Med. 2015; 372:1231-1239
62. World Health Organization. Chikungunya fact sheet. Available here. Accessed April 28, 2025
63. Zurbia-Flores GM, et al. Vaccines. 2023; 11:568

